Picture EBD Group World of Partnering Opportunities 650x100px

Document › Details

Bayer, Max [Fierce Biotech]. (11/6/23). "News: BioNTech Adds Bispecific Candidate, mRNA Delivery Startup as Cancer Work Takes Center Stage".

	Organisation	BioNTech SE (Nasdaq: BNTX)
	Group	BioNTech (Group)
	Organisation 2	AexeRNA Therapeutics Inc.
	Today	BioNTech (Group)
	Group	BioNTech (Group)
	Product	mRNA technology
	Product 2	lipid nanoparticle technology (LNP technology)
	Index term	AexeRNA Therapeutics–BioNTech: investment, 202310 acquisition €na of AexeRNA by BioNTech
	Person	Haag, Thomas A. (Linden Lake Venture Capital + AexeRNA Therapeutics 202311 CEO + Co-Founder)

Original document
accessed by [iito] on 2024-01-06

Record changed: 2024-01-31

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for BioNTech (Group)

[1] Tempus AI, Inc.. (9/4/24). "Press Release: Tempus Announces Real World Data Collaboration with BioNTech". Chicago....
[2] BioNTech SE. (8/22/24). "Press Release: Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine". New York, NY & Mainz....
[3] BioNTech SE. (8/19/24). "Press Release: Lift of Partial Clinical Hold for BNT326/YL202"....
[4] BioNTech SE. (8/16/24). "Press Release: Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age". New York, NY & Mainz....
[5] BioNTech SE. (8/5/24). "Press Release: BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update". Mainz....
[6] BioNTech SE. (6/24/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer". Mainz & Shanghai....
[7] BioNTech SE. (3/20/24). "Press Release: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer". Mainz....
[8] BioNTech SE. (2/8/24). "Press Release: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs". Mainz & London....
[9] BioNTech SE. (1/31/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305". Mainz & Shanghai....
[10] BioNTech SE. (1/22/24). "Press Release: BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer". Mainz & Shanghai....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]